Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rho-associated coiled-coil-containing protein kinase pathway

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Kidera, Yasuhiro ^a,b   Tsubaki, Masanobu ^a   Yamazoe, Yuzuru ^a,b   Shoji, Kaori ^c   Nakamura, Haruyuki ^c   Ogaki, Mitsuhiko ^c   Satou, Takao ^d   Itoh, Tatsuki ^d   Isozaki, Misako ^a,b   Kaneko, Junichi ^a   Tanimori, Yoshihiro ^a,b   Yanae, Masashi ^a,d   Nishida, Shozo ^a  

^a KINKI UNIVERSITY   (Japan)

^b KINDAI UNIVERSITY HOSPITAL   (Japan)

^c Department of Pharmacy   (Japan)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ALPHA2 INTEGRIN; ALPHA4 INTEGRIN; ALPHA5 INTEGRIN; ANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 4; FIBRONECTIN; FLUINDOSTATIN; GELATINASE A; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAMININ; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MESSENGER RNA; MYOSIN LIGHT CHAIN; PROTEIN KINASE; RHO KINASE; SIMVASTATIN; UNCLASSIFIED DRUG; VARY LATE ANTIGEN; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; INTEGRIN; LIM KINASE; MONOUNSATURATED FATTY ACID; PROTEIN KINASE INHIBITOR; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SCLEROPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CELL ADHESION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; LUNG METASTASIS; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CELL MOTION; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; EXPERIMENTAL MELANOMA; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; METABOLISM; ORAL DRUG ADMINISTRATION; PHOSPHORYLATION; TIME;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELL SURVIVAL; EXTRACELLULAR MATRIX PROTEINS; FATTY ACIDS, MONOUNSATURATED; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; INTEGRINS; LIM KINASES; LUNG NEOPLASMS; MATRIX METALLOPROTEINASES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MYOSIN LIGHT CHAINS; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHO GTP-BINDING PROTEINS; RHO-ASSOCIATED KINASES; RNA, MESSENGER; SIGNAL TRANSDUCTION; SIMVASTATIN; TIME FACTORS;

EID: 77956565365     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-127     Document Type: Article

References (45)

1. Cutaneous melanoma: available therapy for metastatic disease. AA Tarhini SS Agarwala, Dermatol Ther 2006 19 19 25 10.1111/j.1529-8019.2005.00052.x 16405566
2. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. HL Howe PA Wingo MJ Thun LA Ries HM Rosenberg EG Feigal BK Edwards, J Natl Cancer Inst 2001 93 824 842 10.1093/jnci/93.11.824 11390532
3. General mechanisms of metastasis. EC Woodhouse RF Chuaqui LA Liotta, Cancer 1997 80 1529 1537 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID- CNCR23.0.CO;2-F 9362419
4. Proteases and protease inhibitors in cancer. CJ Van Noorden, Acta Histochem 1998 100 344 354 9842415
5. How matrix metalloproteinases regulate cell behavior. MD Sternlicht Z Werb, Annu Rev Cell Dev Biol 2001 17 463 516 10.1146/annurev.cellbio.17.1.463 11687497
6. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. LM Coussens B Fingleton LM Matrisian, Science 2002 295 2387 2392 10.1126/science.1067100 11923519
7. New functions for the matrix metalloproteinases in cancer progression. M Egeblad Z Werb, Nat Rev Cancer 2002 2 161 174 10.1038/nrc745 11990853
8. Fibronectin, integrins, and growth control. EH Danen KM Yamada, J Cell Physiol 2001 189 1 13 10.1002/jcp.1137 11573199
9. Integrins, tensegrity, and mechanotransduction. DE Ingber, Gravit Space Biol Bull 1997 10 49 55 11540119
10. Tumour-stromal interactions. Integrins and cell adhesions as modulators of mammary cell survival and transformation. MA Chrenek P Wong VM Weaver, Breast Cancer Res 2001 3 224 229 10.1186/bcr300 11434873
11. The role of the integrin family of adhesion molecules in the development of tumors metastatic to the orbit. ME Hartstein AS Grove Jr JJ Woog, Ophthal Plast Reconstr Surg 1997 13 227 238 10.1097/00002341-199712000-00001 9430298
12. Adhesion molecule profile and malignancy of melanocytic lesions. S Moretti L Martini E Berti C Pinzi B Giannotti, Melanoma Res 1993 3 235 239 8219755
13. Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins. J Grünler J Ericsson G Dallner, Biochim Biophys Acta 1994 1212 259 77 8199197
14. Isoprenoid-mediated inhibition of mevalonate synthesis: potential application to cancer. CE Elson DM Peffley P Hentosh H Mo, Proc Soc Exp Biol Med 1999 221 294 311 10.1046/j.1525-1373.1999.d01-87.x 10460692
15. The role of p21ras in receptor tyrosine kinase signalling. GJ Pronk JL Bos, Biochim Biophys Acta 1994 1198 131 147 7819271
16. Rho GTPases and the actin cytoskeleton. A Hall, Science 1998 279 509 514 10.1126/science.279.5350.509 9438836
17. Regulation of the mevalonate pathway. JL Goldstein MS Brown, Nature 1990 343 425 430 10.1038/343425a0 1967820
18. Role for protein geranylgeranylation in adult T-cell leukemia cell survival. M Nonaka S Uota Y Saitoh M Takahashi H Sugimoto T Amet A Arai O Miura N Yamamoto S Yamaoka, Exp Cell Res 2009 315 141 150 10.1016/j.yexcr.2008.10.010 18992741
19. Mevastatin induces apoptosis in HL60 cells dependently on decrease in phosphorylated ERK. S Nishida H Matsuoka M Tsubaki Y Tanimori M Yanae Y Fujii M Iwaki, Mol Cell Biochem 2005 269 109 114 10.1007/s11010-005-3086-0 15786722
20. Synergistic inhibition of lung tumorigenesis by a combination of green tea polyphenols and atorvastatin. G Lu H Xiao H You Y Lin B Snagaski CS Yang, Clin Cancer Res 2008 14 4981 4988 10.1158/1078-0432.CCR-07-1860 18676773
21. Simvastatin-dependent apoptosis in Hodgkin's lymphoma cells and growth impairment of human Hodgkin's tumors in vivo. B von Tresckow EP von Strandmann S Sasse S Tawadros A Engert HP Hansen, Haematologica 2007 92 682 685 10.3324/haematol.11020 17488694
22. Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. DF Alonso HG Farina G Skilton MR Gabri MS De Lorenzo DE Gomez, Breast Cancer Res Treat 1998 50 83 93 10.1023/A:1006058409974 9802623
23. Ionizing radiation-induced E-selectin gene expression and tumor cell adhesion is inhibited by lovastatin and all-trans retinoic acid. T Nübel W Dippold B Kaina G Fritz, Carcinogenesis 2004 25 1335 1344 10.1093/carcin/bgh133 14988223
24. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. A Horiguchi M Sumitomo J Asakuma T Asano T Asano M Hayakawa, Clin Cancer Res 2004 10 8648 8655 10.1158/1078-0432.CCR-04-1568 15623649
25. Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling. WB Zhong YC Liang CY Wang TC Chang WS Lee, Endocr Relat Cancer 2005 12 615 629 10.1677/erc.1.01012 16172195
26. Isoprenylation is necessary for the full invasive potential of RhoA overexpression in human melanoma cells. EA Collisson DC Carranza IY Chen MS Kolodney, J Invest Dermatol 2002 119 1172 1176 10.1046/j.1523-1747.2002.19519.x 12445208
27. Genomic analysis of metastasis reveals an essential role for RhoC. EA Clark TR Golub ES Lander RO Hynes, Nature 2000 406 532 535 10.1038/35020106 10952316
28. Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor. T Kusama M Mukai M Tatsuta Y Matsumoto H Nakamura M Inoue, Clin Exp Metastasis 2003 20 561 567 10.1023/A:1025898316728 14598891
29. Inhibition of transendothelial migration and invasion of human breast cancer cells by preventing geranylgeranylation of Rho. T Kusama M Mukai M Tatsuta H Nakamura M Inoue, Int J Oncol 2006 29 217 223 16773203
30. A novel third generation bisphosphonate, minodronate (YM529), prevented proliferation and migration of hepatocellular carcinoma cells through inhibition of mevalonate pathway. T Kogure Y Ueno O Kimura Y Kondo J Inoue K Fukushima T Iwasaki T Shimosegawa, Hepatol Res 2009 39 479 489 10.1111/j.1872-034X.2008. 00484.x 19207585
31. Anticancer effects of zoledronic acid against human osteosarcoma cells. B Kubista K Trieb F Sevelda C Toma F Arrich P Heffeter L Elbling H Sutterlüty K Scotlandi R Kotz M Micksche W Berger, J Orthop Res 2006 24 1145 1152 10.1002/jor.20129 16602111
32. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. LA Liotta K Tryggvason S Garbisa I Hart CM Foltz S Shafie, Nature 1980 284 67 68 10.1038/284067a0 6243750 (Pubitemid 10098769)
33. Matrix metalloproteinases in human melanoma. UB Hofmann JR Westphal GN Van Muijen DJ Ruiter, J Invest Dermatol 2000 115 337 344 10.1046/j.1523-1747. 2000.00068.x 10951266
34. Overexpression of RhoA-GTP induces activation of the epidermal growth factor receptor, dephosphorylation of focal adhesion kinase and increased motility in breast cancer cells. M Cceres J Guerrero J Martínez, Exp Cell Res 2005 309 229 238 10.1016/j.yexcr.2005.05.020 15963982
35. The small Gtpase ras is involved in growth factor-regulated expression of the alpha1 integrin subunit in PC12 cells. K Danker N Mechai L Lucka W Reutter R Horstkorte, Biol Chem 2001 382 969 972 10.1515/BC.2001.121 11501763
36. Organized migration of epithelial cells requires control of adhesion and protrusion through Rho kinase effectors. AM Hopkins AA Pineda LM Winfree GT Brown MG Laukoetter A Nusrat, Am J Physiol Gastrointest Liver Physiol 2007 292 806 G817 10.1152/ajpgi.00333.2006 17138966
37. Lim kinases, regulators of actin dynamics. O Bernard, Int J Biochem Cell Biol 2007 39 1071 1076 10.1016/j.biocel.2006.11.011 17188549
38. Rho GTPases in cancer cell biology. FM Vega AJ Ridley, FEBS Lett 2008 582 2093 2101 10.1016/j.febslet.2008.04.039 18460342
39. Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. D Barkan H Kleinman JL Simmons H Asmussen AK Kamaraju MJ Hoenorhoff ZY Liu SV Costes EH Cho S Lockett C Khanna AF Chambers JE Green, Cancer Res 2008 68 6241 6250 10.1158/0008-5472.CAN-07-6849 18676848
40. Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits tumor metastasis in mouse melanoma through suppression of the Rho/ROCK pathway. Y Tanimori M Tsubaki Y Yamazoe T Satou T Itoh Y Kidera M Yanae C Yamamoto J Kaneko S Nishida, Clin Exp Metastasis
41. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. T Kusama M Mukai T Iwasaki M Tatsuta Y Matsumoto H Akedo M Inoue H Nakamura, Gastroenterology 2002 122 308 317 10.1053/gast.2002.31093 11832446
42. Inhibitory effects of tumor necrosis factor-alpha on migration of human periodontal ligament cells. A Takemura I Nakagawa S Kawai H Inaba T Kato S Hamada A Amano, J Periodontol 2006 77 883 890 10.1902/jop.2006.050192 16671882
43. The statins as anticancer agents. KK Chan AM Oza LL Siu, Clin Cancer Res 2003 9 10 19 12538446
44. Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells. HG Farina DR Bublik DF Alonso DE Gomez, Clin Exp Metastasis 2002 19 551 559 10.1023/A:1020355621043 12405293
45. A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of bone turnover in multiple myeloma. TE Sondergaard PT Pedersen TL Andersen K Søe T Lund B Ostergaard P Garnero JM Delaisse T Plesner, Hematol Oncol 2009 27 17 22 10.1002/hon.869 18668701